TickerTalks
Browse all tickers →
TickerTalks›$NUTX
NUNUTX

Nutex Health, Inc.

$NUTX·$1.5B·Medical - Care Facilities·Healthcare
$212.74-3.4%YTD+28.1%1Y+100.3%
Price updated 12h ago·X counts updated 2d ago
NUNUTX
$NUTXNutex Health, Inc.
$212.74-3.35%16 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NUTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

16X posts · last 7 days
Sep 11Sep 27
Mixed sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-17

Nutex Health chatter is mixed. Bulls buy more at $163.50 and $153 on the way down (from $200 to $162), framing NUTX as a real-estate + healthcare + AI play paving a brighter future, with a 14-month weekly rectangle in play and $193 flip-to-support unlocking upside. Bears call NUTX a regulatory loophole masquerading as a healthcare business - 30%+ EBITDA margins driven by gaming the No Surprises Act IDR process (winning 85%+ of arbitrations) - eventually susceptible to payor or regulator action closing the faucet.

Read what X is saying about $NUTX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NUTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-28

The move is getting stronger, with heavier trading behind it.

Nutex Health is up 127% over 12 months at 97% of the 52-week range — Fifth Circuit No Surprises Act ruling favors providers plus Q2 EPS beat +89% on the micro-hospital franchise.

Nutex Health is a technology-powered micro-hospital and physician-network franchise (21 locations across 8 states, MSO services, cloud-based clinical platform) — a business firing on a specific regulatory catalyst and heavy revenue acceleration. The stock is up 127% over 12 months.

  • Q2 was a real beat: EPS $9.38 vs $4.95 estimate (+89%), and the prior four quarters have run 60-329% surprise beats — legitimate operating leverage from the No Surprises Act arbitration wins (85%+ of cases).
  • The Aug 13 Fifth Circuit en banc ruling in Texas Medical Association v. HHS is the specific catalyst: vacates 'ghost rates' in QPA calculations, requires bonus/incentive payments included — materially raises the QPA benchmark, which favors providers like Nutex.
  • Governance mixed: Sept 22 approved dual listing on Nasdaq Texas (small positive), and the cybersecurity breach (Aug 31/Sept 11 updates) exposes PHI with class-action risk — real legal overhang layered onto the operational momentum.

Q3 earnings on Nov 17 is the confirmation — a beat plus firm QPA-attribution and cybersecurity-remediation commentary extends the leg; a soft QPA-benchmark-implementation timing signal or worsening cyber-litigation and the tape cools.

What to watch: Q3 earnings on Nov 17 — a beat plus firm QPA-attribution and cybersecurity-remediation commentary extends the leg; a soft QPA-benchmark-implementation timing signal or worsening cyber-litigation and the tape cools.

On the calendar: 2026-11-17 — Q3 earnings

no surprises act rulingcybersecurity breachnasdaq texas dual listing

Read the AI verdict on $NUTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Healthcare company developing and operating micro-hospital and freestanding emergency room facilities alongside a population health management platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $NUTX.

Medical - Care Facilities · Healthcare

Hospital system revenue recovery continues as elective procedure volumes normalize and commercial insurance mix improves; Medicaid rate cuts from state budget pressures and CMS site-neutral payment proposals are the margin headwinds. AI revenue cycle automation is reducing denials and accelerating reimbursement timelines, improving cash conversion for systems that adopt it.

What this means for $NUTX

Partial — Healthcare company developing and operating micro-hospital and freestanding emergency room facilities alongside a population health management platform.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+15.9%YTD
+13.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
7.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
33.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
43.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
20.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
48.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
51.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$9.38$4.95+89.5%
Q1 2026Apr 30, 2026$6.52$3.99+63.4%
Q4 2025Mar 5, 2026$1.61$5.56-71.0%
Q3 2025Nov 19, 2025$7.76$1.81+328.7%
Next earningsTue, Nov 17·consensus EPS $5.71

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$210.8M-13.6%67.0%57.8%$9.58$31.7M
Q1 FY26$216.5M+2.2%42.4%37.5%$6.70$74.3M
Q4 FY25$151.7M-41.1%30.4%20.4%$1.68$69.0M
Q3 FY25$267.8M+239.9%57.8%48.7%$8.27$99.2M

Forward consensus

3-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$872.0M$863.2M – $884.8M$27.79$27.43 – $28.333
FY27$964.2M$954.5M – $978.4M$27.87$27.51 – $28.413
FY28$1.0B$1.0B – $1.0B$25.34$25.01 – $25.821

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+15.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+45.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 3.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.025-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 18Scott J SaundersDirector203 sh$43K
+ 11 other (4 exempts · 4 awards · 3 others) in window

See when $NUTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial eventAug 318-K — Item 1.05
AI summary

Nuvation Bio Inc. (NUTX) disclosed on September 1, 2026 via 8-K Item 1.05 (Cybersecurity Incidents) that an unauthorized third party gained access to its systems and potentially accessed or exfiltrated data including employee personal information and protected health information. The company is investigating the incident with cybersecurity experts, has notified law enforcement, and class action litigation has already been filed. A material cybersecurity breach at a clinical-stage biotech exposing employee and patient PHI, with class action risk adding legal liability on top of operational disruption.

8-KMaterial agreementJul 218-K — Item 1.01: Material agreement
AI summary

Nutex Health (NUTX) filed an 8-K on July 22, 2026 (event date July 15) under Item 1.01, announcing a material definitive agreement. The excerpt is the cover page; the counterparty and agreement terms are in the body. Nutex Health operates micro-hospitals and hospital-based physician practices; material agreements often relate to new facility development, physician group acquisitions, or financing arrangements.

8-KShareholder voteApr 238-K — Item 5.07: Shareholder vote
+ 11 other (3 routine 8-Ks · 2 earnings 8-Ks · 2 10-Qs · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nutex Health: A High-Risk, High-Reward Play For Speculative Investorsseekingalpha.com·3d agoNutex Health: The Stock Has Had A Great Run, But New Guidance Justifies A Higher Target Price (Rating Upgrade)seekingalpha.com·5d agoNutex Health Approved for Dual Listing on Nasdaq Texasprnewswire.com·7d agoInsider Selling: Nutex Health (NASDAQ:NUTX) Director Sells $43,492.75 in Stockdefenseworld.net·8d ago5 Stocks With Recent Price Strength Amid a Volatile Septemberzacks.com·12d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$THC$ASTH$STLN$CON$AVAH$NHC$PNTG
Voices on X · last 7 days

No standout posts about $NUTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport